Inovio BioMedical INO - Swine Flu Stock to Watch
Inovio´s SynCon influenza vaccines were developed prior to the emergence of the new H1N1 virus strain and have yielded strong protective responses in animal models against a variety of unmatched swine flu virus and bird flu virus.
This gives Inovio an advantage as its vaccines are not strain specific. The DNA vaccines achieved good results during testing, and provided protection against the current influenza strains circulating, including the H1N1 virus and its mutating forms.
Inovio also currently have two flu vaccines at late stages of the product pipeline. Their VGX-3400 and its universal influenza vaccine have also shown positive results during development and trial stages.
Being one of the smallest biotech companies working in the swine flu vaccine, Inovio would have to work together with top pharmaceutical companies to boost the production and distribution capability of their patented technology.
Some of the largest distribution networks in the pharmaceutical industry include GlazoSmithKline (GSK), AstraZeneca (AZN) and Sanofi Aventis (SNY). However, other companies like AVI BioPharma (AVII) and Antigenics (AGEN) also play a key role in the flu vaccine development.
Inovio BioMedical Corporation Company Overview
Inovio Biomedical Corp. is a small company focused on the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent or treat cancers and chronic infectious diseases.
Inovio has strong intellectual property, comprised of the knowledge and expertise of its people, its vaccine design and development processes as well as DNA delivery devices, and its patents.
The company has well-built research and development sectors and 2008 sales reached $2.1 Million (US). The company jumped 165% in one single day in late July 2009 on the back of new developments reports on the DNA vaccine for the flu virus strains.